The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An analysis of the prevalence of HER2 and KRAS mutations, and ALK rearrangements and clinical outcomes in Cancer and Leukemia Group B [CALGB (Alliance)] trial 30406 in advanced non-small cell lung cancer (NSCLC).
Tom Stinchcombe
No relevant relationships to disclose
Lynette M. Sholl
No relevant relationships to disclose
Xiaofei F. Wang
No relevant relationships to disclose
Lin Gu
No relevant relationships to disclose
Mark A. Socinski
No relevant relationships to disclose
Scott J. Rodig
No relevant relationships to disclose
Marzia Capelletti
No relevant relationships to disclose
Jeffrey Crawford
Research Funding - Cancer and Leukemia Group B
Other Remuneration - Cancer and Leukemia Group B
Martin J. Edelman
No relevant relationships to disclose
Miguel Angel Villalona-Calero
No relevant relationships to disclose
Robert Arthur Kratzke
No relevant relationships to disclose
Everett E. Vokes
No relevant relationships to disclose
Vincent A. Miller
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine
Pasi Antero Janne
Consultant or Advisory Role - Abbott Laboratories; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Genentech; LabCorp; Pfizer (U); Roche; Sanofi